甲状腺结节细针抽吸物中 BRAF V600E 突变分析与其超声分类的关系:用于选择分子分析样本的潜在指南。
BRAF V600E mutation analysis of thyroid nodules needle aspirates in relation to their ultrasongraphic classification: a potential guide for selection of samples for molecular analysis.
机构信息
Department of Radiology and Center for Imaging Science, Sungkyunkwan University School of Medicine, Seoul, South Korea.
出版信息
Thyroid. 2010 Mar;20(3):273-9. doi: 10.1089/thy.2009.0226.
BACKGROUND
Proper candidates to improve the effectiveness of molecular testing for thyroid nodules detected on ultrasonography (US) in a clinical setting are not well known. We aimed at evaluating the effective indication and method of BRAF(V600E) mutation analysis of aspiration specimens according to the US features of thyroid nodules in a BRAF(V600E) mutation-prevalent area.
METHODS
A total of 244 patients with 244 thyroid nodules were prospectively classified as malignant and nonmalignant based on US. Thyroid nodules with any malignant US features including spiculated margin, the presence of microcalcifications or macrocalcifications, marked hypoechogenicity, or a taller-than-wide shape were defined as US-positives and those without these features were defined as US-negatives. All patients underwent US-guided fine-needle aspiration (FNA). The presence of the BRAF(V600E) mutation in FNA specimens was determined by allele-specific polymerase chain reaction (AS-PCR) and direct DNA sequencing. The mutation results were correlated with cytology and either surgical pathology or follow-up.
RESULTS
Of 244 nodules, 66 were US-positive and 178 were US-negative. The malignancy rate was 92% (61/66) for US-positives and 14% (25/178) for US-negatives. The BRAF(V600E) mutation was identified in 67% (44/66) of US-positives and in 10% (17/178) of US-negatives. The BRAF(V600E) mutation for nodules with indeterminate or nondiagnostic cytology was present in 45% (5/11) of US-positives and in 8% (2/26) of US-negatives (p = 0.0168). A false negative cytology with the mutation was found in only one case of the US-negatives. All nodules with the mutation were surgically confirmed as papillary carcinomas. Adding the genetic analysis to the FNA as compared with the FNA alone improved the sensitivity and accuracy for US-positives, whereas there was no significant improvement for US-negatives. With regard to sensitivity and accuracy, the use of the AS-PCR was better than the use of the direct DNA sequencing for US-positives as compared with US-negatives.
CONCLUSION
The application of BRAF(V600E) mutation analysis in FNA specimens is more effective for thyroid nodules with malignant US features as compared with nodules without malignant US features. The use of the AS-PCR is more valuable as compared with the direct DNA sequencing to refine the diagnosis in a clinical setting.
背景
在临床环境中,提高超声(US)检测到的甲状腺结节进行分子检测有效性的合适患者尚不清楚。我们的目的是评估 BRAF(V600E) 突变分析在 BRAF(V600E) 突变流行地区根据甲状腺结节的 US 特征在抽吸标本中的有效适应证和方法。
方法
共 244 例 244 个甲状腺结节前瞻性地根据 US 分为恶性和非恶性。具有任何恶性 US 特征的甲状腺结节,包括锯齿状边缘、微钙化或大钙化的存在、明显的低回声或更高的宽形,定义为 US 阳性,没有这些特征的定义为 US 阴性。所有患者均行 US 引导下细针抽吸(FNA)。通过等位基因特异性聚合酶链反应(AS-PCR)和直接 DNA 测序确定 FNA 标本中 BRAF(V600E) 突变的存在。突变结果与细胞学、手术病理学或随访相关。
结果
244 个结节中,66 个为 US 阳性,178 个为 US 阴性。US 阳性的恶性率为 92%(61/66),US 阴性的恶性率为 14%(25/178)。BRAF(V600E) 突变在 67%(44/66)的 US 阳性和 10%(17/178)的 US 阴性中被发现。具有不确定或非诊断性细胞学的结节中 BRAF(V600E) 突变的存在率为 45%(5/11)的 US 阳性和 8%(2/26)的 US 阴性(p=0.0168)。US 阴性病例中仅发现一例假阴性细胞学。所有具有突变的结节均经手术证实为乳头状癌。与单独进行 FNA 相比,将基因分析添加到 FNA 中可提高 US 阳性的敏感性和准确性,而对 US 阴性则没有显著提高。就敏感性和准确性而言,与 US 阴性相比,AS-PCR 的应用优于直接 DNA 测序用于 US 阳性。
结论
与无恶性 US 特征的结节相比,BRAF(V600E) 突变分析在具有恶性 US 特征的甲状腺结节中的应用更为有效。与直接 DNA 测序相比,AS-PCR 的应用更有价值,可在临床环境中细化诊断。